Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. - Wikidata - wikimedia - TriplyDB

Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.

Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.

http://www.wikidata.org/entity/Q44062340

about

Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients Prophylactic Measures During Induction for Acute Myeloid Leukemia.Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients.Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.Canadian clinical practice guidelines for invasive candidiasis in adults.Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Febrile neutropenia in hematologic malignancies.Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.Invasive aspergillosis in patients with hematologic malignancies.Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.Levels of total fungus and Aspergillus on a pediatric hematopoietic stem cell transplant unit.Novel approaches to antifungal prophylaxis.Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients.Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.Clinical implications of environmental sources for Aspergillus.Use of antifungal drugs in hematology Antifungal prophylaxis following reduced-intensity stem cell transplantation.Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies.Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.Attenuation of itraconazole fungicidal activity following preexposure of Aspergillus fumigatus to fluconazole Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?Management of fungal infections following allogeneic stem cell transplantation.Infection Pattern of Neutropenic Patients in Post-chemotherapy Phase of Acute Leukemia Treatment.Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia.Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.Managing fungal and viral infections in pediatric leukemia.Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice.Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.Two cases of aspergillus endocarditis in non neutropenic children on chemotherapy for acute lymphoblastic leukaemia.Risk factors for fluconazole-resistant candidemia.

P2860

Q24193785-0B255BCC-E308-4E43-92AE-4CB571768A42 Q30235496-7AFB7AED-0881-43C1-969B-C395EE326FCE Q30887333-0C254209-A138-4BBB-8841-0B3B85C9E4E7 Q33270075-07E21D4E-DA72-464F-B1F8-CB728A4504E3 Q33849298-48C347C2-071F-4991-B661-C7F246E22FF3 Q34218399-9D05B2FD-24B7-45C2-9B66-6CD8A0BD6E24 Q34237335-2F785459-D062-4871-AFD5-846B402C5BE4 Q34490092-F98B17F0-8218-4AB9-BC8F-297FA9FF92A2 Q34532546-0DBC2F54-F5CD-46E7-9BDB-1FFDB6065DC9 Q34655730-381E82A0-3EB9-49B1-B3EE-A67CEDAEBC16 Q34667166-86191B55-15F9-42DC-9BD4-540F0A80BFC2 Q35616161-E78D8CC4-3053-47A8-ACEF-FAEFB4D0661E Q35659502-AB5E647C-F0F0-4B23-95CD-C2C6A8A9FDAA Q35659664-EC65755C-9D62-414C-9E78-2997B833D179 Q35763847-CA4279EB-AD40-4B5E-8B66-54E74564AF13 Q35790799-D1598C4B-F8A0-46CF-A98E-378A1C445470 Q35833407-708B822D-F339-488F-A2DE-15A6811EDB39 Q35912756-2CE85DDF-5B4F-4E48-8601-297DF079AE66 Q36235068-7148FAAE-3DCA-4B76-978F-451E91FC4483 Q36364856-17A78E4E-4638-4CC5-AF2F-DA86E357BC26 Q36658236-F36C49B7-6198-454B-AA4D-09C6608E1AD8 Q36670916-E2D8A153-5244-4133-8C89-9D8D03D908A4 Q36714507-499A3DDE-534E-4944-9CE4-6517FF50FDE1 Q36880695-6CAD75B7-2806-4229-A56F-918E71EFF288 Q36934269-7E1B97FD-9D16-47F6-9ADD-B0199A14E40F Q37043539-50E0AA71-A6AC-408A-8019-9057006CF8B1 Q37098160-170D09B8-FB2F-4009-B0AF-AAC930ECC56C Q37202860-EE2581C2-CE3D-4EB3-8FC9-A7B7BC3EDC14 Q37442571-90016AF7-AEFF-442D-8016-2958ED722889 Q37528435-136974D1-05C4-427C-AA93-ED4BB2D236B0 Q37568382-25350657-5B07-40F2-AB03-C49A6AEA713D Q37810281-C7897C3D-C881-4D9E-B97C-B81E58F1828E Q37866827-EF8F2B2A-CCA1-47EE-941C-5C91DB28A51E Q37993110-EA7F8364-16B5-4EA3-9751-80B3D629AFD1 Q38178526-D348C215-D3B0-4562-9C13-A139778F52C4 Q38196743-3CBA4A52-218E-45E0-9EFC-9AE300F9FA0C Q38284455-41FCFEB2-1B39-486D-886E-AAB49CA2525E Q38871233-23A3E397-F479-4AD8-AA50-55B1275E29CF Q39805612-46F0D81E-E67F-40AA-8B82-F12D344330B4 Q39934814-17D93614-5B83-4F79-AE82-D989CBF1E01E

P2860

Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.

http://www.wikidata.org/entity/Q44062340

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Antifungal prophylaxis for sev ...... ed-controlled clinical trials.

@en

Antifungal prophylaxis for sev ...... ed-controlled clinical trials.

@nl

type

label

Antifungal prophylaxis for sev ...... ed-controlled clinical trials.

@en

Antifungal prophylaxis for sev ...... ed-controlled clinical trials.

@nl

prefLabel

Antifungal prophylaxis for sev ...... ed-controlled clinical trials.

@en

Antifungal prophylaxis for sev ...... ed-controlled clinical trials.

@nl

P1433

Q44062340-BDB109AC-4AF3-40C3-970E-A36ACAC1DC65

P1476

Q44062340-63671C3B-F710-4B2F-84F8-E748910B10D5

P2093

Q44062340-3E0A0838-FD15-41DB-87DE-9A477BC98125

Q44062340-8F04934E-D708-45A9-A766-C2FA34A3E98D

Q44062340-A8352F8A-04BA-4DE0-96F3-4792F1B0D5F7

Q44062340-B0187AC4-7313-45A0-A842-34D27A8501EC

Q44062340-CC3155DC-6CB5-48D4-9308-A542071DFDBC

Q44062340-F58585B9-6841-48AD-A5D9-59ABF68672B9

P2860

Q44062340-02A21BB8-FA83-4AE8-9C13-90CC9A7254CD

Q44062340-03F7DDFB-41B6-4CDE-BC00-B7ABB9EE7AF4

Q44062340-054C8728-8099-4A8F-A6A8-D94995C5EA4E

Q44062340-11FC0035-2FD3-4A42-A89B-112EE13FCC7E

Q44062340-12ED15AD-6234-4619-9C81-17443B1E77ED

Q44062340-1349250B-2B6D-4438-82DE-A94DED9A5A0F

Q44062340-2DD27AB7-A1CD-47BD-86E9-8AC01E7BFB12

Q44062340-326F37DC-5E2C-4048-9772-46EF8800E187

Q44062340-401DF23B-16BA-4C25-8563-AFB86C023435

Q44062340-43B37563-404E-471D-BEBA-F401DCB2BE52

P304

Q44062340-C1A5D16F-5FEA-478C-8363-CEC4D2801845

P31

Q44062340-42D0924F-E154-45A9-ABFA-1060E5449598

Q44062340-6fc40036-0796-46fe-9be6-9ef4d5b185b8

P356

Q44062340-4A92F51C-7F72-4D7C-B54C-7A2CC515EA54

P407

Q44062340-4F8C3389-D8BC-4DC3-B48B-32FB877CADDB

P433

Q44062340-C6DF0387-D9DE-4898-A4B9-24AEDE1027B8

P478

Q44062340-1C66CEAF-0AAD-4F0F-9B42-59B925919587

P577

Q44062340-6E1782A5-4268-4F8E-BD4A-BF039B71C88C

P5875

Q44062340-E856984E-E769-45FC-A043-16C4C4615102

P698

Q44062340-7E052790-A3B3-49CD-AA75-2263BE431318

P921

Q44062340-9ADE35FB-9026-47D7-92F6-250F503F67EF

P356

P1433

P1476

Antifungal prophylaxis for sev ...... ed-controlled clinical trials.

@en

P2093

Coleman Rotstein

http://www.w3.org/2001/XMLSchema#string

Eric J Bow

http://www.w3.org/2001/XMLSchema#string

Mary S Cheang

http://www.w3.org/2001/XMLSchema#string

Michel Laverdière

http://www.w3.org/2001/XMLSchema#string

Nathalie Lussier

http://www.w3.org/2001/XMLSchema#string

Stratis Ioannou

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

Meta-analysis in clinical trials

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

An assessment of clinically useful measures of the consequences of treatment

Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

Meta-analysis in clinical research

Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial.

Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.

P304

3230-3246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.10610

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227643886

http://www.w3.org/2001/XMLSchema#string

P698

12115356

http://www.w3.org/2001/XMLSchema#string

P921